Imcivree
Payments companies reported to CMS as associated with Imcivree. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Imcivree, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Imcivree
These are the largest totals companies reported as associated with Imcivree. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Christy Davis | Jackson, MS | Family | $19,207.58 |
| Jose Gamez-Godoy | Edinburg, TX | Pediatric Endocrinology | $15,360.33 |
| Katie Queen | Bogalusa, LA | Pediatrics | $13,857.46 |
| Jennifer Paisley | Lawrenceburg, IN | Internal Medicine | $11,033.75 |
| Juliana Simonetti | Boston, MA | Internal Medicine | $10,913.52 |
| Uzoma Okorie | Marshfield, WI | Pediatric Cardiology | $10,424.47 |
| Svetlana Ten | Staten Island, NY | Pediatric Endocrinology | $10,253.96 |
| Heidi Shea | Plano, TX | Endocrinology, Diabetes & Metabolism | $9,159.29 |
| Jesse Richards | Tulsa, OK | Internal Medicine | $9,048.52 |
| Vidhu Thaker | New York, NY | Pediatric Endocrinology | $8,093.56 |
Prescribed Imcivree?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.